Abcam, ab215268, Anti-ADAM17 antibody [D1 (A12)] - BSA and Azide free

Size: 150µg
Human Monoclonal ADAM17 antibody. Carrier free. Suitable for FuncS and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human ADAM17.
Key facts
Host species:Human,
Clonality:Monoclonal,
Clone number:D1 (A12),
Isotype:IgG1,
Carrier free:Yes,
Reacts with:Human,
Applications:FuncSSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human ADAM17. The exact immunogen used to generate this antibody is proprietary information.P78536

Product details:
ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound TACE-specific noncatalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the TACE catalytic domain. The resulting "cross-domain" human IgG1 antibody [D1(A12)] ab215268 is a previously undescribed biochemically holistic ADAM ectodomain inhibitor and demonstrates a unique alternative to small-molecule metalloprotease inhibition.
Note from inventor: ab215268 is conformation sensitive and sees only a specific form of the native enzyme (reflecting its redox state). It does not work by IHC or WB. It was designed as a potential drug, active in native situations.

Properties and Storage Information:
Form-Liquid, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ADAM17 also known as TACE (tumor necrosis factor-alpha converting enzyme) is a metalloprotease belonging to the ADAM (a disintegrin and metalloprotease) family. This protein functions by cleaving and shedding extracellular portions of cell surface proteins. It weighs approximately 93 kDa. ADAM17 is expressed in a range of tissues including the heart liver kidney and brain. The protein plays a role in the regulation of various biological processes through the activation and inactivation of membrane-bound precursor proteins.
Biological function summary
The ADAM17 protein regulates a multitude of cellular responses such as inflammation and growth factor signaling. It is not part of a complex but interacts with various substrates in the cell membrane. ADAM17 cleaves precursors to release soluble cytokines and growth factors like tumor necrosis factor-alpha (TNF-alpha) and epidermal growth factor receptor (EGFR) ligands which modulate cell proliferation migration and apoptosis.
Pathways
ADAM17 plays an integral role in both the TNF and EGFR signaling pathways. These pathways are important in maintaining normal cellular homeostasis. ADAM17 interacts with proteins like TNF receptors and ligands of the EGFR family integrating signaling that affects immune response and cell growth. The regulatory function of ADAM17 in these pathways makes it an important target for modulating cellular responses triggered by external stimuli.
ADAM17 has significant implications in conditions such as rheumatoid arthritis and cancer. In rheumatoid arthritis the protein's shedding activity influences inflammatory cytokines contributing to the disease’s pathogenesis alongside proteins like TNF-alpha. In cancer ADAM17's ability to release EGFR ligands affects tumor cell proliferation and metastasis with interactions involving EGFR proteins. It is a target of therapeutic interest with research focused on developing inhibitors to manage these diseases effectively.